<DOC>
	<DOCNO>NCT03063203</DOCNO>
	<brief_summary>In study , investigator seek determine whether decitabine therapy improve outcome , specifically overall survival select subset acute myeloid leukemia ( AML ) patient poorest prognosis base refractoriness induction treatment high risk genetic mutation .</brief_summary>
	<brief_title>Single Agent Decitabine TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>TP53 mutant relapsed/refractory AML follow 7+3 ( similar cytarabine contain induction chemotherapy AML ) disease detect one follow method : bone marrow blast &gt; 5 % , Hematologics flow cytometry assay ( threshold &gt; 0.5 % ) ( alternative equivalent assay may substitute ) , Persistent cytogenetic abnormality ( e.g . del5 , del17p , etc ) , FISH conventional karotyping , Persistent TP53 mutation ( least 5 variant read least 50x coverage ) . Patients &gt; 10 % blast day +14 bone marrow biopsy follow 7+3 may either enrol may treat course standard reinduction ( e.g . 5+2 similar ) reevaluate response . Eligible patient meet criterion subsequent biopsy . The presence TP53 mutation determine Genoptix ( institutional prefer equivalent assay ) patient . Detection TP53 mutation time initial diagnosis sufficient enrollment . Detection TP53 mutation either peripheral blood bone marrow adequate enrollment . Bone marrow organ function define : Peripheral white blood cell count &lt; 50,000/mcl ( patient may receive hydroxyurea necessary cytoreduction ) , Total bilirubin &lt; 1.5 x upper limit normal , AST ALT &lt; 2.5 x upper limit normal , Serum creatinine &lt; 2.0 x upper limit normal , , At least 18 year age . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable Prior treatment either decitabine azacitidine . Acute promyelocytic leukemia PMLRARA ( 15 ; 17 ) . Active HIV , Hepatitis B , Hepatitis C infection . Concurrent illness include , limited , ongoing uncontrolled infection , symptomatic NYHA class 3 4 congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Radiation therapy within 14 day enrollment . Chemotherapy administration 14 day precede enrollment exception hydroxyurea , continue Cycle 2 . A washout period oral tyrosine kinase inhibitor ( e.g . Jakafi , etc ) require , although tyrosine kinase inhibitor therapy must discontinue prior enrollment . Malignancies require active therapy , exception basal cell squamous cell carcinoma skin treat local resection carcinoma situ cervix . Currently receive investigational agent . Known central nervous system ( CNS ) leukemia . A history allergic reaction attribute compound similar chemical biologic composition decitabine agent use study . Pregnant and/or breastfeed . Women childbearing potential must negative urine pregnancy test within 7 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>